全部资讯｜CELL INTELLIGENCE

Tailoring Therapy for Frail and Elderly Myeloma Patients.

PubMed 2026/09/25 发表Cancer JQ3 · IF 2.1（JCR 2025）

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

PubMed 2026/09/03 发表BloodQ1 · IF 23.9（JCR 2025）

Dynamic Targetable Extracellular Vesicle Surface Proteins Monitor Depth of Response to CAR T Therapy.

PubMed 2026/03/18 发表Res Sq

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

PubMed 2025/12/05 发表Hematology Am Soc Hematol Educ ProgramQ1 · IF 3.7（JCR 2025）

Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.

PubMed 2025/06/20 发表Front OncolQ2 · IF 3.4（JCR 2025）

The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies.

PubMed 2025/02/05 发表Cancers (Basel)Q2 · IF 4.8（JCR 2025）

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

PubMed 2024/06/04 发表Int J Mol SciQ1 · IF 5.6（JCR 2025）

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma.

PubMed 2024/05/10 发表Front OncolQ2 · IF 3.4（JCR 2025）

Targeting GPRC5D in multiple myeloma.

PubMed 2024/04/16 发表Expert Rev Anticancer TherQ3 · IF 3（JCR 2025）

我们提出了关于各类基于 GPRC5D 的疗法在 MM 治疗格局中潜在应用的见解，无论是单独使用还是与已有疗法联合。

Integrating Immune Therapies for the Treatment of Multiple Myeloma.

PubMed 2023/12/01 发表J Natl Compr Canc NetwQ1 · IF 17.5（JCR 2025）

全部资讯 10